Re: FDA Preapproval Inspection - Submitting a 505b2 for a combination product to the
Who will be the lead FDA modality, i.e. CDRH, CBER, CDER, other? Is there any room for reasonable disagreement as to the lists of important regulatory issues from the two (I assume) modalities?
If you're sure you understand how they'll approach the product, I think you are most of the way to your answer. If on the other hand you don't have any idea what their individual reactions will be or if they'll have compatible views, that's a tougher situation.